Eli Lilly (LLY) Q2 Revenue Jumps 38%

Eli Lilly (NYSE:LLY), a leading pharmaceutical company known for its focus on diabetes, obesity, oncology, and neuroscience, posted its results on August 7, 2025. The key headline was a significant beat on both revenue (GAAP) and earnings (non-GAAP), powered by strong volume growth in its diabetes and obesity medicines. Revenue (GAAP) hit $15.56 billion versus GAAP expectations of $14.70 billion, while Non-GAAP EPS landed at $6.31 compared to estimates of $5.60. This performance reflects continued robust demand for therapies like Zepbound and Mounjaro, exceeding even aggressive analyst forecasts, as non-GAAP EPS of $6.31 exceeded the analyst estimate of $5.60. With a 38% increase in revenue (GAAP) and 61% earnings growth (non-GAAP EPS) year over year, the quarter showed notable acceleration in core franchises, as reflected by strong growth in key products revenue—leading management to raise guidance for FY2025. Despite ongoing pricing and access challenges, overall momentum in sales, margins, and the pipeline resulted in a strong period for the company. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Eli Lilly is a leading global pharmaceutical manufacturer with a focus on chronic diseases including diabetes, obesity, oncology, immunology, and neuroscience. The company stands out for its heavy investment in research and development (R&D), employing around 11,000 people in these activities. Its business is built on continuous drug innovation and its ability to replace aging products with new therapies—a crucial need in pharma due to patent expirations.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool